| Bioactivity | FC9402 is a potent and selective sulfide quinone oxidoreductase (SQOR) inhibitor extracted from patent WO 2020/146636 A1. FC9402 attenuates TAC-induced cardiomyocyte hypertrophy and left ventricle (LV) fibrosis. FC9402 can be used for cardiovascular regulation[1]. | ||||||||||||
| Target | SQOR | ||||||||||||
| Invitro | FC9402 attenuates TAC-induced cardiomyocyte hypertrophy and left ventricle (LV) fibrosis[1]. | ||||||||||||
| Name | FC9402 | ||||||||||||
| CAS | 2452401-65-7 | ||||||||||||
| Formula | C19H16N4O | ||||||||||||
| Molar Mass | 316.36 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. WO 2020/146636 A1 |